JERUSALEM, May 17, 2011 /PRNewswire-FirstCall/ -- Medisafe 1 Technologies Corp. (OTCBB: MFTH), a developer of patentedtechnologies that physically prevent unauthorized administration of prescription medications, announced today that the company has initiated discussions and negotiations with a Group of Engineers that have developed a Major Medical ( Patent Pending )Breakthrough
The Technology embodies a band that is worn by individuals who are prone to possible need of Medical Care. The Band detects and will send an automatic alert of the vital signs of the related individual showing the possible need of imminent intensive medical care required . This advanced alert will save many lives where unfortunately medical care is reached and attended to at a late stage.
Medisafe 1 Technologies continues to seek to expand and to market Medical Technology that saves lives and / or reduce the amount of Medical casualties . This unique Medical Product will enhance the group of Products of Medisafe 1 Technologies Corp.
About Medisafe 1 Technologies
Medisafe 1 Technologies seeks to effectively prevent unauthorized administration of a drug or medicinal substance by hypodermic needle. Medisafe's patented technology is a medical assembly with a locking mechanism that is intended to ensure the substance cannot be released from the hypodermic needle without positive pre-matching between the substance and its intended patient.
This letter contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 as amended and Section 21E of the Securities Exchange Act of 1934 as amended. All forward-looking statements are inherently uncertain, based on current expectations and assumptions concerning future events or future performance of Medisafe 1 Technologies Corp., and its technologies. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release, as actual results may differ materially from those indicated. Medisafe 1 Technologies Corp. public filings may be viewed at http://www.sec.gov.
Contact: Jacob Elhadad Jacob.Elhadad10@gmail.com +972-5244-4-0000
Subscribe to our Free Newsletters!